Kura Oncology (KURA) Change in Accured Expenses (2010 - 2026)
Kura Oncology (KURA) reported Change in Accured Expenses of -$16.2 million for Q1 2026, down 88.25% year-over-year from -$138.0 million in Q1 2025, and down 650.74% on a QoQ basis from -$2.2 million in Q4 2025.
Kura Oncology (KURA) has 14 years of Change in Accured Expenses data on file, last reported at -$16.2 million in Q1 2026.
- Quarterly Change in Accured Expenses fell 88.25% year-over-year to -$16.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.1 million (down 55.45% YoY) and the FY2025 annual result came in at $12.7 million, down 24.8% from the prior year.
- Change in Accured Expenses eased to -$16.2 million in Q1 2026 per KURA's latest filing, from -$2.2 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $14.3 million in Q4 2024 and bottomed at -$16.2 million in Q1 2026.
- The 5-year median for Change in Accured Expenses is -$50000.0 (2024), against an average of $1.4 million.
- The widest annual swing landed in 2022, when Change in Accured Expenses slumped 5132.26%; it then surged 21524.0% in 2025.
- Tracing KURA's Change in Accured Expenses over 5 years: stood at -$1.6 million in 2022, then surged by 649.36% to $8.6 million in 2023, then jumped by 67.2% to $14.3 million in 2024, then tumbled by 115.07% to -$2.2 million in 2025, then tumbled by 650.74% to -$16.2 million in 2026.
- Per Business Quant, the three latest KURA Change in Accured Expenses figures stand at -$16.2 million (Q1 2026), -$2.2 million (Q4 2025), and $12.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Kura Oncology | 801.92 Mn | 801.92 Mn | 18.00 Mn | -16.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.22 Mn |
| Mar 31, 2026 | -16.22 Mn |
| Dec 31, 2025 | -2.16 Mn |
| Dec 31, 2025 | -2.16 Mn |
| Sep 30, 2025 | 12.72 Mn |
| Sep 30, 2025 | 12.72 Mn |
| Jun 30, 2025 | 10.71 Mn |
| Jun 30, 2025 | 10.71 Mn |
| Mar 31, 2025 | -8.61 Mn |
| Mar 31, 2025 | -8.61 Mn |
| Dec 31, 2024 | 14.33 Mn |
| Dec 31, 2024 | 14.33 Mn |
| Sep 30, 2024 | 5.68 Mn |
| Sep 30, 2024 | 5.68 Mn |
| Jun 30, 2024 | -50,000.00 |
| Jun 30, 2024 | -50,000.00 |
| Mar 31, 2024 | -3.13 Mn |
| Mar 31, 2024 | -3.13 Mn |
| Dec 31, 2023 | 8.57 Mn |
| Dec 31, 2023 | 8.57 Mn |
| Sep 30, 2023 | 3.93 Mn |
| Sep 30, 2023 | 3.93 Mn |
| Jun 30, 2023 | 4.11 Mn |
| Jun 30, 2023 | 4.11 Mn |
| Mar 31, 2023 | -5.36 Mn |
| Mar 31, 2023 | -5.36 Mn |
| Dec 31, 2022 | -1.56 Mn |
| Dec 31, 2022 | -1.56 Mn |
| Sep 30, 2022 | 6.35 Mn |
| Sep 30, 2022 | 6.35 Mn |
| Jun 30, 2022 | -341,000.00 |
| Jun 30, 2022 | -341,000.00 |
| Mar 31, 2022 | -5.25 Mn |
| Mar 31, 2022 | -5.25 Mn |
| Dec 31, 2021 | 31,000.00 |
| Dec 31, 2021 | 31,000.00 |
| Sep 30, 2021 | 139,000.00 |
| Sep 30, 2021 | 139,000.00 |
| Jun 30, 2021 | -1.24 Mn |
| Jun 30, 2021 | -1.24 Mn |
| Mar 31, 2021 | -1.45 Mn |
| Mar 31, 2021 | -1.45 Mn |
| Dec 31, 2020 | 3.68 Mn |
| Dec 31, 2020 | 3.68 Mn |
| Sep 30, 2020 | 2.53 Mn |
| Sep 30, 2020 | 2.53 Mn |
| Jun 30, 2020 | 1.85 Mn |
| Jun 30, 2020 | 1.85 Mn |
| Mar 31, 2020 | -2.39 Mn |
| Mar 31, 2020 | -2.39 Mn |
| Dec 31, 2019 | 2.09 Mn |
| Dec 31, 2019 | 2.09 Mn |
| Sep 30, 2019 | 2.07 Mn |
| Sep 30, 2019 | 2.07 Mn |
| Jun 30, 2019 | -1.24 Mn |
| Jun 30, 2019 | -1.24 Mn |
| Mar 31, 2019 | -2.07 Mn |
| Mar 31, 2019 | -2.07 Mn |
| Dec 31, 2015 | 251,000.00 |
| Dec 31, 2015 | 251,000.00 |
| Sep 30, 2015 | 1.18 Mn |
| Sep 30, 2015 | 1.18 Mn |
| Jun 30, 2015 | 2.29 Mn |
| Jun 30, 2015 | 2.29 Mn |
| Mar 31, 2015 | -907,000.00 |
| Mar 31, 2015 | -907,000.00 |
| Dec 31, 2014 | 833,000.00 |
| Dec 31, 2014 | 833,000.00 |
| Sep 30, 2014 | 60,000.00 |
| Sep 30, 2014 | 60,000.00 |
| Jun 30, 2014 | -4,203.00 |
| Jun 30, 2014 | -4,203.00 |
| Mar 31, 2014 | 1,628.00 |
| Mar 31, 2014 | 1,628.00 |
| Dec 31, 2013 | 8,377.00 |
| Dec 31, 2013 | 8,377.00 |
| Sep 30, 2013 | -5,050.00 |
| Sep 30, 2013 | -5,050.00 |
| Jun 30, 2013 | 6,550.00 |
| Jun 30, 2013 | 6,550.00 |
| Mar 31, 2013 | -4,000.00 |
| Mar 31, 2013 | -4,000.00 |
| Dec 31, 2012 | 8,974.00 |
| Dec 31, 2012 | 8,974.00 |
| Sep 30, 2012 | -6,403.00 |
| Sep 30, 2012 | -6,403.00 |
| Jun 30, 2012 | 6,403.00 |
| Jun 30, 2012 | 6,403.00 |
| Mar 31, 2012 | -4,000.00 |
| Mar 31, 2012 | -4,000.00 |
| Dec 31, 2011 | 7,438.00 |
| Dec 31, 2011 | 7,438.00 |
| Sep 30, 2011 | -5,623.00 |
| Sep 30, 2011 | -5,623.00 |
| Jun 30, 2011 | 897.00 |
| Jun 30, 2011 | 897.00 |
| Mar 31, 2011 | 888.00 |
| Mar 31, 2011 | 888.00 |
| Dec 31, 2010 | 2,720.00 |
| Dec 31, 2010 | 2,720.00 |
| Sep 30, 2010 | -970.00 |
| Sep 30, 2010 | -970.00 |